The agonist lovastatin can enhance the activity of SHP2 and promote the chemotherapeutic effect in colon cancer by activating the cGAS-STING signaling pathway, which could be a better alternative for colon cancer treatment [106]. Here, CGAS is linked to malignant colon neoplasm.